Ionics Pharmaceuticals

Ionis Pharmaceuticals is a leader in RNA-targeted therapeutics, specializing in the development of antisense oligonucleotides (ASOs) to treat a wide range of diseases. The company has pioneered the field of RNA medicine, successfully bringing several blockbuster drugs to market, including Spinraza for spinal muscular atrophy and Tegsedi for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Ionis maintains a robust and diverse pipeline targeting cardiovascular, metabolic, neurological, and rare diseases. By utilizing its proprietary technology platform, the company can precisely target the genetic drivers of disease, often addressing conditions that are unreachable by traditional small molecule or antibody-based therapies. Ionis operates through both independent development and strategic partnerships with major pharmaceutical companies to maximize the reach of its innovative medicines.